Cemiplimab, an anti–programmed cell death-1 (PD-1) monoclonal antibody has been approved for use in combination with chemotherapy as a first-line treatment for patients with advanced NSCLC, regardless of PD-L1 expression levels. This evidence concerns the gene CD274 and non-small cell lung carcinoma.